These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8571992)

  • 1. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
    Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.
    van der Gaast A; Hulshof C; Kok TC; van Loon E; Splinter TA
    Eur J Cancer; 1993; 29A(6):870-3. PubMed ID: 8484981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
    Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
    Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA-125 measurements > 65 U/mL. Clinical value.
    Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
    J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
    Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
    Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 549 as a marker in breast cancer.
    Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
    Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
    Jezersek B; Cervek J; Rudolf Z; Novaković S
    Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
    Shabana A; Onsrud M
    Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
    Yenisey C; Güner G
    Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
    Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
    Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
    Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen.
    Kopczyński Z; Thielemann A
    Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
    Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
    Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.